[18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography

[1]  Sanjiv S. Gambhir,et al.  Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.

[2]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  A. Bruskin,et al.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  L. Abrahmsén,et al.  Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy , 2007, Expert opinion on biological therapy.

[6]  A. Bruskin,et al.  In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. , 2007, Bioconjugate chemistry.

[7]  R. Pehrson,et al.  Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.

[8]  S. Gambhir,et al.  PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Sanjiv S Gambhir,et al.  PET of vascular endothelial growth factor receptor expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Funda Meric-Bernstam,et al.  Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy , 2006, Clinical Cancer Research.

[11]  Vladimir Tolmachev,et al.  111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Carlsson,et al.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.

[13]  G. Adams,et al.  Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[15]  G. D'alessio,et al.  Biological properties of a human compact anti-ErbB2 antibody. , 2005, Carcinogenesis.

[16]  V. Tolmachev,et al.  Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. , 2005, Bioconjugate chemistry.

[17]  H. Burstein,et al.  The distinctive nature of HER2-positive breast cancers. , 2005, The New England journal of medicine.

[18]  J. Zidan,et al.  Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease , 2005, British Journal of Cancer.

[19]  S. Gambhir,et al.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. , 2005, Cancer research.

[20]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  M. Untch,et al.  A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab , 2005, Expert opinion on biological therapy.

[22]  Mohan Doss,et al.  Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. , 2005, Cancer research.

[23]  M. Brechbiel,et al.  Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease , 2004, Clinical Cancer Research.

[24]  J. Bart,et al.  Preclinical characterisation of 111In‐DTPA‐trastuzumab , 2004, British journal of pharmacology.

[25]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[26]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.

[27]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[28]  P. Piccini,et al.  Applications of positron emission tomography (PET) in neurology , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  Jinha M. Park,et al.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.

[30]  J. Ross.  Emerging cancer diagnostics. "On slide" or "off slide": that is the question. , 2003, American journal of clinical pathology.

[31]  M. Cobleigh,et al.  Is trastuzumab every three weeks ready for prime time? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[33]  P. Merlet,et al.  In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M. Brechbiel,et al.  Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). , 2002, Cancer research.

[35]  J. Seidel,et al.  Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability , 2001, 2001 IEEE Nuclear Science Symposium Conference Record (Cat. No.01CH37310).

[36]  W C Eckelman,et al.  Development of fluorine-18-labeled 5-HT1A antagonists. , 1999, Journal of medicinal chemistry.

[37]  Ying Ma,et al.  Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. , 2003, Nuclear medicine and biology.

[38]  D. V. Van Dyke,et al.  HER-2/neu Testing in Breast Cancer. , 2003, Journal of the Association of Genetic Technologists.

[39]  A Lanigan,et al.  HER2 as a prognostic and predictive marker for breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  M. Dowsett,et al.  Assessment of HER2 status in breast cancer: why, when and how? , 2000, European journal of cancer.